Home » Stocks » ZIOP

ZIOPHARM Oncology Inc. (ZIOP)

Stock Price: $5.33 USD 0.68 (14.62%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $5.52 +0.19 (3.57%) Feb 26, 7:59 PM
Market Cap 1.14B
Revenue (ttm) n/a
Net Income (ttm) -72.95M
Shares Out 212.84M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $5.33
Previous Close $4.65
Change ($) 0.68
Change (%) 14.62%
Day's Open 4.85
Day's Range 4.78 - 5.57
Day's Volume 6,656,132
52-Week Range 1.79 - 5.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 2 days ago

Investors reacted positively to FDA clearance to begin a clinical study and Ziopharm's CEO change.

GlobeNewsWire - 1 week ago

Company to Hold R&D Day on Thursday, March 11, 2021 Company to Hold R&D Day on Thursday, March 11, 2021

The Motley Fool - 3 weeks ago

An ugly board of directors skirmish came to an end.

GlobeNewsWire - 3 weeks ago

BOSTON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Boar...

GlobeNewsWire - 1 month ago

– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation –

GlobeNewsWire - 2 months ago

BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Zi...

GlobeNewsWire - 2 months ago

– Advances Eden BioCell's clinical program to validate Rapid Personalized Manufacturing (RPM) –

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Ziopharm (ZIOP) stock based on the movements in the options market lately.

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), a sizable and long-term shareholder of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (...

GlobeNewsWire - 2 months ago

Jaime Vieser and Holger Weis Elected to Board of Directors Jaime Vieser and Holger Weis Elected to Board of Directors

GlobeNewsWire - 2 months ago

BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that Satyavrat “Sath” Shukla, CFA, Chief Financial Officer, has ...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”) today responded to the latest element of the low-road campaign that Ziopharm Onc...

GlobeNewsWire - 2 months ago

Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card

GlobeNewsWire - 2 months ago

Recommends A gainst E lecting WaterMill Nominee Jaime Vieser

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation bene...

GlobeNewsWire - 2 months ago

Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading proxy ad...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation bene...

GlobeNewsWire - 3 months ago

ISS Acknowledges Ziopharm's Outperformance of its Peer Group During Chairman Scott Tarriff's Tenure

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation bene...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation bene...

GlobeNewsWire - 3 months ago

Co ntinues to Execute on Strategy to Ensure Strong Long-Term Outlook

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation bene...

GlobeNewsWire - 3 months ago

– First Data from Ongoing Phase 2 Study of Controlled IL-12 in Combination with Cemiplimab Demonstrate Promising Safety Profile in rGBM,  and a Confirmed Partial Response –

GlobeNewsWire - 3 months ago

– Pharmaceutical Executive with 2 0 + Year s of Experience Across All Phases of Clinical Research Including IND Submission s , Trial Design and Regulatory Filings –

GlobeNewsWire - 3 months ago

– Special Advisor and Former Chief of Staff for the Bill & Melinda Gates Medical Research Institute Joins as Independent Director –

GlobeNewsWire - 3 months ago

BOSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to partic...

Business Wire - 3 months ago

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Level One Partners, LLC, (“Level One Partners”) along with all of its related entities, will vote 100% of its approximately 10.68 million shares of Zioph...

Seeking Alpha - 3 months ago

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q3 2020 Results - Earnings Call Transcript

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation bene...

GlobeNewsWire - 3 months ago

Urges Shareholders to Sign and Return Ziopharm's GREEN Consent Revocation Card

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation bene...

GlobeNewsWire - 4 months ago

BOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it has received a notice, and acknowledges the filing of, a...

GlobeNewsWire - 4 months ago

BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to partic...

Investopedia - 5 months ago

This month's collection of penny stocks has little in common beyond rock-bottom prices and promising technical chart patterns.

Other stocks mentioned: BBAR, EDRY, EOD, GEN
GlobeNewsWire - 5 months ago

– Life Sciences industry veteran; 15-year Cephalon executive, serving progressively  as CFO, COO and then CEO at time of $6.8 billion acquisition by Teva –

GlobeNewsWire - 5 months ago

BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of four additional members to its Scientifi...

The Motley Fool - 5 months ago

One of the biotech's pipeline candidates won a key FDA designation.

GlobeNewsWire - 5 months ago

BOSTON, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the U.S. Food and Drug Administration (FDA) has granted ...

GlobeNewsWire - 5 months ago

BOSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to par...

Seeking Alpha - 6 months ago

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 7 months ago

BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, August 6, at 4:30 pm EDT to...

GlobeNewsWire - 7 months ago

– Industry veteran entrepreneur with 20+ years’ experience founding and financing successful, innovative biotech companies including GenScript and Legend Biotech –

GlobeNewsWire - 7 months ago

- RPM leverages the Sleeping Beauty system to reduce cost and simplify production for CD19-specific CAR-T infusion the day after gene transfer - - RPM leverages the Sleeping Beauty system to r...

GlobeNewsWire - 7 months ago

BOSTON, July 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the first patient with diffuse intrinsic pontine glioma (...

GlobeNewsWire - 8 months ago

BOSTON, June 22, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that 36 subjects have been enrolled in the phase 2 clinical tr...

Zacks Investment Research - 8 months ago

Investors need to pay close attention to Ziopharm Oncology (ZIOP) stock based on the movements in the options market lately.

GlobeNewsWire - 8 months ago

BOSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of renowned oncology and immunotherapy pione...

GlobeNewsWire - 8 months ago

BOSTON, June 12, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to part...

GlobeNewsWire - 9 months ago

Dr. David Mauney stepping down as President; Remains a consultant to the Company Dr. David Mauney stepping down as President; Remains a consultant to the Company

About ZIOP

ZIOPHARM Oncology, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12,... [Read more...]

Industry
Biotechnology
CEO
Dr. Laurence James Neil Cooper
Stock Exchange
NASDAQ
Ticker Symbol
ZIOP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for ZIOP stock is "Buy." The 12-month stock price forecast is 5.93, which is an increase of 11.26% from the latest price.

Price Target
$5.93
(11.26% upside)
Analyst Consensus: Buy